The Dow's Triple-Digit Gains Left These Stocks Behind

Investors can never predict whether the market will rise or fall on any given day, but lately, a pretty good bet has been to expect some substantial volatility in one direction or the other. For the sixth straight day, the Dow Jones Industrials (DJINDICES: ^DJI  ) made a triple-digit move, with today's result being a 138-point gain that signaled investor optimism that the Federal Reserve will remain in control of the markets even after tomorrow's announcement following the Fed's latest meeting. The U.S. market remains a pocket of strength amid less exuberant markets around the world, with rioting in Brazil marking the latest uprising among populations dissatisfied with the sluggish conditions in various economies across the globe.

Only a couple of stocks posted losses today. Merck (NYSE: MRK  ) fell 0.1% in light of a Supreme Court decision that gave the Federal Trade Commission the power to challenge arrangements between primary-drug developers and generic-drug manufacturers that involve upfront payments in exchange for delays in releasing generic versions of name-brand drugs. Clearly, Merck and its peers have incentives to keep brand-name profits going as long as possible, and FTC challenges could reduce their ability to do so going forward.

Microsoft (NASDAQ: MSFT  ) also posted the narrowest of losses. Reports that the company will turn to Qualcomm (NASDAQ: QCOM  ) to supply some chips for new versions of its Surface RT tablet were bad news for NVIDIA, which is the existing supplier for the Surface RT, but probably didn't move Microsoft's own stock substantially. In any event, the newer Surface Pro seems like a better prospect for Microsoft going forward, given its ability to run full versions of Windows 8 programs despite its heftier price tag.

Finally, outside the Dow, MannKind (NASDAQ: MNKD  ) fell 12%, extending its losses from yesterday after completing its phase 3 trial of its Afrezza treatment for type 2 diabetes. MannKind's management couldn't identify any fundamental news affecting the stock, although later comments from CFO Matthew Pfeffer concerning whether the company might seek a partner before getting an approval decision on Afrezza from the FDA weren't sufficient to wipe out all of the stock's losses. The volatility highlights the danger of investing in small stocks with substantial speculative elements in their results.

Merck stumbled into 2013 and continues to battle patent expirations and pipeline problems. Is Merck still a solid dividend play, or should investors be looking elsewhere? In a new premium research report on Merck, the Fool tackles all of the company's moving parts, its major market opportunities, and reasons to both buy and sell. To find out more click here to claim your copy today.


Read/Post Comments (1) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 19, 2013, at 8:05 AM, crt6978 wrote:

    The article MotleyFool published bashing MNKD and a misstatement from Flyonthewall didn't help matters concerning share price for MNKD yesterday.Add a bear raid by HF and MM managers and of course share price will go down.37+million shares were moved from retail to big money managers hands.Does this show lack of conviction in MNKD...quite the contrary,big money wants their hands on as many shares as they can get because they believe Aug.results will be terrific and Afrezza will be approved.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2496978, ~/Articles/ArticleHandler.aspx, 10/22/2014 8:03:42 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement